Xin Lang Cai Jing·2025-10-20 07:29Core Viewpoint - Haiprime is a leading multinational pharmaceutical company with a focus on heparin, biopharmaceutical CDMO, and innovative drug development, benefiting from the depreciation of the RMB and a strong overseas revenue stream [2][3]. Company Overview - Established in 1998 in Shenzhen, Haiprime operates with both A and H share financing platforms, primarily engaged in the heparin industry chain, biopharmaceutical CDMO, and innovative drug investment, development, and commercialization [2]. - The company's main business revenue composition includes: 63.06% from formulations, 18.59% from CDMO, 16.05% from heparin sodium and low molecular weight heparin raw materials, and 2.30% from other sources [7]. Financial Performance - For the first half of 2025, Haiprime reported a revenue of 2.817 billion yuan, a year-on-year decrease of 0.71%, and a net profit attributable to shareholders of 422 million yuan, down 36.44% year-on-year [7]. - As of June 30, 2025, the company had a total market capitalization of 17.153 billion yuan, with a trading volume of 35.1323 million yuan on October 20, 2023 [1][7]. Market Position - Haiprime's overseas revenue accounted for 93.04% of its total revenue, benefiting from the depreciation of the RMB [3]. - The company is positioned within the pharmaceutical and biotechnology sector, specifically in chemical pharmaceuticals and chemical preparations [7]. Shareholder Information - As of June 30, 2025, Haiprime had 26,300 shareholders, a decrease of 7.29% from the previous period, with an average of 0 shares per shareholder [7]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 6.3765 million shares to 11.3176 million shares [9]. Dividend Distribution - Since its A-share listing, Haiprime has distributed a total of 4.21 billion yuan in dividends, with 514 million yuan distributed over the past three years [8].